Phenomix and Mayo Clinic Use AI to Predict GLP-1 Side Effects

Phenomix Sciences and Mayo Clinic have unveiled a new study demonstrating the use of AI algorithms to predict side effects from GLP-1 therapies, specifically nausea. Announced in a press release, the study was presented at Digestive Disease Week 2025 and highlights the potential for more personalized obesity care.

The research, led by Dr. Andres Acosta and presented by Dr. Thomas Fredrick, utilized a machine learning-assisted Genetic Risk Score (GRS) to analyze genetic data from 110 participants. The findings revealed that patients with a high GRS were more than twice as likely to experience nausea from liraglutide, a common GLP-1 medication, compared to those with a low score.

This predictive capability is significant as nausea is a prevalent side effect of GLP-1 therapies, affecting up to 40% of patients and causing some to discontinue treatment. By identifying patients at higher risk for side effects, the study aims to improve treatment tolerability and adherence, while also enhancing clinical trial design and pharmaceutical development.